$CAI

4 stories mentioning CAIUpdated 4d ago

Every FINWIRES story that references CAI, newest first.

What are analysts saying about CAI?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on CAI?

Caris Life Sciences Insider Sold Shares Worth $12,132,080, According to a Recent SEC Filing

Brian J Brille, Director, Vice Chairman and Executive Vice President, on September 17, 2026, sold 400,000 shares in Caris Life Sciences (CAI) for $12,132,080. Following the Form 4 filing with the SEC, Brille has control over a total of 730,303 common shares of the company, with 230,303 shares held directly and 500,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2019410/000207195926000008/xslF345X05/wk-form4_1789682909.xml

$CAI

Wire71d ago

BofA Adjusts Price Target on Caris Life Sciences to $23 From $28

Caris Life Sciences, Inc. (CAI) has an average rating of overweight and mean price target of $27.08, according to analysts polled by FactSet.Price: $17.20, Change: $+0.21, Percent Change: +1.21%

$CAI

Insider Trading133d ago

Caris Life Sciences Insider Bought Shares Worth $501,426, According to a Recent SEC Filing

Jeff L Vacirca, Director, on May 11, 2026, executed a purchase for 31,050 shares in Caris Life Sciences (CAI) for $501,426. Following the Form 4 filing with the SEC, Vacirca has control over a total of 49,671 common shares of the company, with 49,671 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/2019410/000172416126000005/xslF345X05/wk-form4_1778588549.xml

$CAI

Research162d ago

Jefferies Initiates Caris Life Sciences at Buy With $28 Price Target

Caris Life Sciences (CAI) has an average rating of buy and mean price target of $30.79, according to analysts polled by FactSet.

$CAI

Track with the FINWIRES app suite

FolioX

Track CAI in your portfolio

WheelAI

Analyze CAI options with the wheel strategy

StockInsider

See market sentiment on CAI